Our Approach
Developing
breakthrough
products.
We have a robust pipeline of programs to prevent disease progression, improve outcomes and protect against organ damage in cardio, renal and metabolic diseases.
RBT-1 (stannic protoporfin / iron sucrose)
RBT-1 (stannic protoporfin/iron sucrose) is a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and or valve surgery. RBT-1 has started its Phase 3 US registrational study to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations.
RBT-2 (tetrahydrocurcumin)
RBT-2 (tetrahydrocurcumin) is an oral antioxidant and antifibrotic drug that is in IND enabling studies targeting delaying CKD progression.
RBT-3 (iron sucrose)
RBT-3 (iron sucrose), one component of RBT-1, is a novel, low molecular weight iron nanoparticle that has the potential to rapidly restore iron levels and improve blood product utilization in cardiac surgery and/or ER patients. RBT-3 has also demonstrated the potential to mitigate cisplatin induced nephrotoxicity in preclinical models. We are currently exploring opportunities to further the clinical development of RBT-3 in these potential indications.
RBT-9 (Stannic protoporphin)
RBT-9 (stannic protoporfin), another component of RBT-1, is a potent anti-inflammatory and antioxidant drug. It has completed Phase 1 (as part of the RBT-1 program) and has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19. The data from this trial indicated that RBT-9 has the potential to significantly improve clinical outcomes. Additional work is underway to help inform the future clinical development strategy.
Veverimer
Veverimer (Alezuris™) is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in a Phase 2 trial.
Pipeline
Condition
of CKD
Pipeline
Publications
- Morbidity and Mortality Associated With Blood Transfusions in Elective Adult Cardiac Surgery
TaggedPYas Sanaiha, MD, Joseph Hadaya, MD, Arjun Verma, Richard J. Shemin, MD, Michael Madani, MD, Nilas Young, MD, Tobias Deuse, MD, Jack Sun, MD, Peyman Benharash, MD1TaggedEnd, on behalf of theUniversity of California Cardiac Surgery Consortium - Effects of RBT-1 on preconditioning response biomarkers in patients undergoing coronary artery bypass graft or heart valve surgery: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
Andre Lamy , Glenn M. Chertow, Michael Jessen, Alonso Collar, Craig D. Brown, Charles A. Mack, Mohamed Marzouk, Vincent Scavo, T Benton Washburn, David Savage, Julian Smith, Jayme Bennetts, Roland Assi, Christian Shults, Arman Arghami Javed Butler, P.J. Devereaux, Richard Zager, Chao Wang, Steve Snapinn, Bhupinder Singh - RBT-1, a Pharmacologic Preconditioning Agent, Reduces the Incidence of Anemia, Blood Transfusion, and Use of Supplemental Iron in Patients Undergoing Cardiac Surgery
Ashish K Khanna, Kevin W Lobdell, Rakesh C Arora, Stacey Ruiz, Jeannette Rodriguez, Ayrn D O’Connor, Bhupinder Singh, Andre Lamy - A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of RBT-1 Evaluating Cytoprotective Biomarkers & Post-Operative Outcomes in Patients Undergoing Elective Coronary Artery Bypass Graft and/or Valve Surgery on Cardiopulmonary BypassAndre Lamy, MD MSc
- Oxidant- induced preconditioning: A pharmacologic approach for triggering renal ‘self defense’Richard A Zager
- Inhibition of Heme Oxygenase-1 Protects Against Tissue Injury in Carbon Tetrachloride Exposed LiversChristian Eipel, Ph.D., Michaela Eisold, Harald Schuett, and Brigitte Vollmar, M.D., Institute of Experimental Surgery, University of Rostock, Rostock, Germany
- Combined iron sucrose and protoporphyrin treatment protects against ischemic and toxin-mediated acute renal failureRichard A. Zager, MD, Ali CM Johnson, BS, and Kirsten B. Frostad, BS, The Fred Hutchinson Cancer Research Center, and the University of Washington, Seattle, WA
- Parenterial Iron Sucrose- Induced Renal Preconditioning: Differential Ferritin Heavy and Light Chain Expression in Plasma, Urine, and Internal OrgansAli C Johnson, MS, Ted Gooley, PhD, Alvaro Guillem, PhD, Jeff Keyser, PhD, Henrik Rasmussen, MD, Bhupinder Singh, MD§, Richard A Zager, MD, The Fred Hutchinson Cancer Research Center, Seattle WA, the University of Washington, Seattle WA, Renibus Therapeutics, Dallas, TX, and University of California, Irvine
- Heme oxygenase-1 inhibitor tin-protoporphyrin improves liver regeneration after partial hepatectomyMonica Pibiri, Vera Piera Leoni, Luigi Atzori, Department of Biomedical Sciences, Oncology and Molecular Pathology Unit, University of Cagliari, Via Porcell, 09124 Cagliari, Italy
- Quercetin and tin protoporphyrin attenuate hepatic ischemia reperfusion injury: role of HO-1Yara Atef & Hassan M. El-Fayoumi & Yousra Abdel-Mottaleb & Mona F. Mahmoud
- Marked protection against acute renal and hepatic injury following Nitrited- Myoglobin + Tin Protoporphyrin AdministrationRichard A. Zager, MD The Fred Hutchinson Cancer Research Center, Seattle, WA and the University of Washington, Seattle, WA
- Serum Iron Protects from Renal Postischemic InjuryArticle in Journal of the American Society of Nephrology · August 2017
- Preconditioning with tin-protoporphyrin IX attenuates ischemia/reperfusion injury in the rat kidneyTakashi Kaizu, Tohru Tamaki, Mitsuko Tanaka, Yasushi Uchida, Sei-ichiro Tsuchihashi, Akio Kawamura, and Akira Kakita
- Quercetin and tin protoporphyrin attenuate hepatic ischemia reperfusion injury: role of HO-1Yara Atef & Hassan M. El-Fayoumi & Yousra Abdel-Mottaleb & Mona F. Mahmoud
- Inhibition of Heme Oxygenase-1 Protects Against Tissue Injury in Carbon Tetrachloride Exposed LiversChristian Eipel, Ph.D., Michaela Eisold, Harald Schuett, and Brigitte Vollmar, M.D.
- Interim Results of a Phase 2 Study With RBT-1 Evaluating Postoperative Course in Patients Undergoing Elective CABG/Valve Surgery on Cardiopulmonary BypassAndre Lamy MD, MSc
- VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis
Navdeep Tangri, Vandana S. Mathur , David A. Bushinsky, Gerrit Klaerner, Elizabeth Li, Dawn Parsell, Yuri Stasiv, Michael Walker, Donald E. Wesson, David C. Wheeler, Vlado Perkovic, and Lesley A. Inker - Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD
David A. Bushinsky, Thomas Hostetter, Gerrit Klaerner, Yuri Stasiv, Claire Lockey, Sarah McNulty, Angela Lee, Dawn Parsell, Vandana Mathur, Elizabeth Li, Jerry Buysse, and Robert Alpern - Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trialDonald E Wesson, Vandana Mathur, Navdeep Tangri, Yuri Stasiv, Dawn Parsell, Elizabeth Li, Gerrit Klaerner, David A Bushinsky
- Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extensionDonald E Wesson, Vandana Mathur, Navdeep Tangri, Yuri Stasiv, Dawn Parsell, Elizabeth Li, Gerrit Klaerner, David A Bushinsky
- Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney DiseaseGerrit Klaerner, Jun Shao, Kalpesh Biyani, Matthew Kade, Paul Kierstead, Randi Gbur, Scott Tabakman, Son Nguyen, and Jerry Buysse
- PO0283 | A Novel Fast-Acting Iron Sucrose Formulation for CKD Patients with Iron Deficiency AnemiaCharles Cook, Bhupinder Singh, Stacey Ruiz, Alvaro Guillem
- Renibus Iron Sucrose Test Results ReviewCMC SQUARED LLC
- Iron sucrose (‘RBT-3’) activates the hepatic and renal HAMP1 gene, evoking renal hepcidin loading and resistance to cisplatin nephrotoxicityRichard A. Zager, Ali C.M. Johnson, and Renibus Therapeutics
- Parenterial iron sucrose-induced renal preconditioning: differential ferritin heavy and light chain expression in plasma, urine, and internal organsAli C. Johnson, Ted Gooley, Alvaro Guillem, Jeff Keyser, Henrik Rasmussen, Bhupinder Singh, and Richard A. Zager
- Long–Term Renal Outcomes after Cisplatin TreatmentSheron Latcha, Edgar A. Jaimes, Sujata Patil, Ilya G. Glezerman, Swati Mehta, and Carlos D. Flombaum
- Natural products: potential treatments for cisplatin-induced nephrotoxicityChun-yan, Da-yong Lou, Li-qin Zhou, Jin-cheng Wang, Bo Yang, Qiao-jun He, Jia-jia Wang and Qin-jie Weng
- Oxidant- induced preconditioning: A pharmacologic approach for triggering renal ‘self defense’Richard A Zager
- Quercetin and tin protoporphyrin attenuate hepatic ischemia reperfusion injury: role of HO-1Yara Atef & Hassan M. El-Fayoumi & Yousra Abdel-Mottaleb & Mona F. Mahmoud
- Inhibition of Heme Oxygenase-1 Protects Against Tissue Injury in Carbon Tetrachloride Exposed LiversChristian Eipel, Ph.D., Michaela Eisold, Harald Schuett, and Brigitte Vollmar, M.D.
- Dietary tetrahydrocurcumin reduces renal fibrosis and cardiac hypertrophy in 5/6 nephrectomized ratsWei Ling Lau, Mahyar Khazaeli, Javad Savoj, Kasim Manekia, Maria Bangash, Roshni G. Thakurta, Anhthu Dang, Nosratola D. Vaziri, Bhupinder Singh
- Influence of Tetrahydrocurcumin on Hepatic and Renal Functional
Markers and Protein Levels in Experimental Type 2 Diabetic RatsPidaran Murugan and Leelavinothan Pari - Tetrahydrocurcumin Ameliorates Kidney Injury and High Systolic Blood Pressure in High-Fat Diet-Induced Type 2 Diabetic MiceWeerapon Sangartit, Kyung Bong Ha, Eun Soo Lee, Hong Min Kim, Upa Kukongviriyapan, Eun Young Lee, Choon Hee Chung
- Tetrahydrocurcumin protects against sepsis-induced acute kidney injury via the SIRT1 pathwayLu Lia, Xiaoxi Liua, Shasha Lia, Qingyan Wang, Hongru Wang, Menglu Xua and Yanxin An
- Marked protection against acute renal and hepatic injury following Nitrited- Myoglobin + Tin Protoporphyrin AdministrationRichard A. Zager, M.D.
- Distant Organ Dysfunction in Acute Kidney Injury: A ReviewSul A Lee, M.D., Martina Cozzi, M.D., Errol L. Bush, M.D., and Hamid Rabb, M.D.
- Tin Protoporphyrin Provides Protection Following Cerebral Hypoxia-Ischemia: Involvement of Alternative PathwaysBrad A. Sutherland, Odette M. Shaw, Andrew N. Clarkson, Ian C. Winburn, Adam C. Errington, Christine L. Dixon, George Lees, Ivan A. Sammut, and Ian Appleton